Abstract
Viral liver diseases, especially due to hepatitis B virus (HBV) and hepatitis C virus (HCV), were observed with a high frequency in hemodialysis units throughout the world. Due to the deficient immune response of uremic subjects, which renders them unable to eliminate viruses, hemodialysis patients act as reservoirs of the viruses and transmit infection to other patients, to the dialysis unit staff and eventually to their own family, in the case of infection with HBV.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Stevens CE, Taylor PE, Tong MJ, Toy PT, Vyas GN: Hepatitis B vaccine, an overview. in Viral Hepatitis and Liver Disease, edited by Vyas GN, Dienstag JL, Hoofnagle JH, Grune & Stratton, Orlando, 1984, p 275
Tiollais P, Pourcel C, Dejean A: The hepatitis B virus. Nature 317: 489, 1985
Houghton M, Richman K, Han J et al.: Hepatitis C virus (HCV): a relative of the pestiviruses and flaviviruses. in Viral Hepatitis and Liver Disease, edited by Hollinger FB, Lemon SM, Margolis H, Baltimore William & Wilkins, 1991, p 328
Degast GC, Houwen B, Van Der Hem JK, The JH: T lymphocyte number and function and the course of hepatitis B in hemodialysis patients. Infect Immun 14: 1138, 1976
Descamps B, Jungers P, Naret C, Zingraff J, Bach JF: HLA1 B8 phenotype association and HBs antigenemia evolution in 440 hemodialyzed patients. Digestion 15: 171, 1977
Hoofnagle JH, Di Bisceglie AM: Serodiagnosis of acute and chronic hepatitis. Sem Liver Dis 11: 73, 1991
Degott C, Degos F, Jungers P et al.: Relationship between liver histopathological changes and HBs Ag in 111 patients treated by long-term hemodialysis. Liver 3: 377, 1983
Bruguera M, Vidal L, Sanchez-Tapias JM, Casta J, Revert L, Rodes J: Incidence and features of liver disease in patients on chronic hemodialysis. J Clin Gastroenterol 12: 298, 1990
Paterlini P, Gerken G, Nakajima E et al.: Polymerase chain reaction to detect hepatitis B virus DNA and RNA sequences in primary liver cancers from patients negative for hepatitis B surface antigen. N Engl J Med 323: 80, 1990
Colombo M, De Franchis R, Del Ninno E et al.: Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med 325: 675, 1991
Schroeter GPJ, Weill R, Penn I et al.: Hepatocellular carcinoma associated with hepatitis B infection after kidney transplantation. Lancet 2: 381, 1982
Degos F, Degott C, Benhamou JP, Liver bibpsy. in Oxford Textbook of Clinical Hepatology, edited by Mac-Intyre N, Benhamou JP, Bircher J, Rizzetto M, Rodes J, Oxford University Press 1991, p 320
Lebrec D, Goldfarb G, Degott C, Rueff B, Benhamou JP: Transvenous liver biopsy; an experience based on 1000 hepatic tissue samplings with this procedure. Gastroenterology 83: 338, 1982
Scheuer PJ: Classification of chronic viral hepatitis; need for reassessment. J Hepatol 13: 372, 1991
Knodell RG, Ishak KG, Black WC et al.: Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1: 431, 1981
Gilli P, Cavazzini L, Stabellini N, Malacame F, Soffritti S, Storari A: Histological features of non-A non-B hepatitis in hemodialysis patients. Nephron 61: 296. 1992
Parfrey PS, Forbes RDC, Hutchinson TA, Beaudoin JG, Dauphinee WD, Guttmann RD: The prevalence and progression of liver disease in renal transplant recipients: a histological study. Transplant Proc 16: 1103, 1984
Chu CM, Karayiannis P, Fowler MJF, Monjardino J. Liaw YF, Thomas HC: Natural history of chronic hepatitis B virus infection in Taiwan: studies of hepatitis B virus DNA in serum. Hepatology 5: 431, 1985
Lau JYN, Wright TL: Molecular virology and pathogenesis of hepatitis B. Lancet 342: 1335, 1993
Fujita YK, Kamata K, Kamena H, Isselbacher KJ, Wands JR: Detection of hepatitis B virus infection in hepatitis B surface antigen-negative hemodialysis patients by monoclonal radioimmunoassays. Gastroenterology 91: 1357, 1986
Brechot C, Degos F, Lugassy C et al.: Hepatitis B virus DNA in patients with chronic liver disease and negative tests for hepatitis B surface antigen. N Engl J Med 312: 270, 1985
Gerken G, Paterlini P, Manns M et al.: Assay of hepatitis B virus DNA by polymerase chain reaction and its relationship to pre-S and S-encoded viral surface antigens. Hepatology 13: 158, 1991
Nordenfeldt E, Lindholm T, Lofgren B, Moestrup T, Reinicke V: Different categories of chronic H&sAg carriers; a long term follow-up. in Viral Hepatitis, edited by Szmuness W, Alter HJ, Maynard JE, Philadelphia, Franklin Institute Press, 1981, p 237
Theilmann L, Gmelin K, Rambausek M et al.: HBV DNA and other hepatitis B virus markers in sera from long-term hemodialysis and kidney transplant patients. Hepatogastroenterol 35: 147, 1988
Degos F, Lugassy C, Degott C et al.: HBV and HBV related viral infection in renal transplant recipients: a prospective study of 90 patients. Gastroenterology 94: 151, 1988
Hanson CA, Sutherland DE, Snover D: Fulminant hepatic failure in an HBsAg carrier renal transplant recipient following cessation of immunosuppressive therapy. Transplantation 39: 311, 1985
Marcellin P, Giostra E, Martinot Peignoux M et al.: Redevelopment of hepatitis B surface antigen after renal transplantation. Gastroenterology 100: 1432, 1991
Carman W, Thomas H, Domingo E: Viral genetic variation: hepatitis B virus as a clinical example. Lancet 341: 349, 1993
Bonino F, Brunette MR, Rizzetto M, Will H: Hepatitis B virus unable to secrete e antigen. Gastroenterology 100: 1138, 1991
Carman WF, Jacyna MR, Hadziyannis S et al.: Mutation preventing formation of hepatitis B antigen in patients with chronic hepatitis B infection. Lancet 2: 588, 1989
Kremsdorf D, Thiers V, Garreau F et al.: Nucleotide sequence analysis of hepatitis B virus genomes isolated from serologically negative patients. in Viral Hepatitis and Liver Disease, edited by Hollinger FB, Lemon SM, Margolis, HS, Baltimore, William & Wilkins, 1991, p 222
Brechot C: Polymerase chain reaction for the diagnosis of hepatitis B and C viral hepatitis. J Hepatol 17: 35, 1993
Thiers V, Nakajima E, Kremsdorf D et al.: Transmission of hepatitis B from hepatitis-B-seronegative subjects. Lancet 2: 1273, 1988
Rizzetto M, Ponzetto A, Bonino F, Smedile A: Hepatitis Delta virus infection. Clinical and epidemiological aspects. in Viral Hepatitis and Liver Disease, edited by Zuckerman A, New York, Alan R Liss, 1988, p 389
Pol S, Dubois F, Mattlinger B et al.: Absence of hepatitis Delta virus infection in chronic hemodialysis and kidney transplant patients in France. Transplantation 54: 1096, 1992
Kharsha G, Degott C, Degos F, Carnot F, Potet F, Kreis H: Fulminant hepatitis in renal transplant recipients: the role of the Delta agent. Transplantation 44: 221, 1987
Ware AJ, Gorder NL, Gurian LE, Douglas C, Shorey JW, Parker T: Value of screening for markers of hepatitis in dialysis units. Hepatology 3: 513, 1983
Perillo RP: Treatment of chronic hepatitis B. in Viral Hepatatis LiverDisease, edited by Hollinger FB, Lemon SM, Margolis HS, Baltimore, William & Wilkins, 1991, p 616
Peters M: Mechanisms of action of interferons. Semin Liv Dis 9: 235, 1989
Davis G: Interferon treatment of viral hepatitis in immunocompromised patients. Semin Liv Dis 9: 267, 1989
Hirsch MS, Tolkoff-Rubin NE, Kelly AP, Rubin RH: Pharmakokinetics of human and recombinant leukocyte interferon in patients with chronic renal failure who are undergoing hemodialysis. J Infect Dis 148: 335, 1983
Buisson C, Degos F, Daniel F et al.: Pharmakokinetics of interferon Alpha 2b in hemodialysis. Nephrol Dial Transpl 9: 977, 1994
Marcellin P, Ouzan D, Degos F et al.: Randomized controlled trial of adenine arabinoside 5’ monophosphate (ARA-AMP) in chronic active hepatitis: comparison of the efficacy in heterosexual and homosexual patients. Hepatology 10: 328, 1989
Pol S, Saltiel C, Legendre C et al.: Efficacy of Arabinoside 5’ monophosphate in kidney recipients with chronic active hepatitis B: a pilot study. Transplant Proc 25: 1446, 1993
Degos F, Degott C: Hepatitis in renal transplant recipients. J Hepatol 9: 114, 1989
Dusheiko G, Song E, Bowyer S et al.: Natural history of hepatitis B virus infection in renal transplant recipients. A fifteen years follow-up. Hepatology 3: 330, 1983
Ware AJ, Luby JP, Eigenbrodt EH, Long DL, Hull AR: Spectrum of liver disease in renal transplant recipients. Gastroenterology 68: 755, 1975
LaQuaglia MP, Tolkoff-Rubin NE, Dienstag JL et al.: Impact of hepatitis on renal transplantation. Transplantation 32: 504, 1981
Parfrey PS, Forbes RDC, Hutchinson TA: The impact of renal transplantation on the course of hepatitis B liver disease. Transplantation 39: 610, 1985
Degos F, Debure A, Kreis H: Hepatitis in renal transplant recipients. Transplantation Reviews 1: 159, 1987
Pol S, Debure A, Degott C et al.: Chronic hepatitis in kidney allograft recipients. Lancet 335: 878, 1990
Rao JV, Kasiske BL, Anderson WR: Variability in the morphological spectrum and clinical outcome of chronic liver disease in hepatitis B-positive and B-negative renal transplant recipients. Transplantation 51: 391, 1991
Rao JV, Anderson WR, Kasiske BL, Dahl DC: Value of liver biopsy in the evaluation and management of chronic liver diseases in renal transplant recipients. Am J Med 94: 241, 1993
Fairley CK, Mijch A, Gust ID, Nichilson S, Dimitrakakis M, Lucas CR: The increased risk of fatal liver disease in renal transplant patients who are hepatitis Be antigen and/or HBV DNA positive. Transplantation 52: 497, 1991
Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M: Isolation of a cDNA clone derived from a blood borne NANB viral hepatitis genome. Science 244: 359, 1989
Kuo G: An assay for circulating antibodies to a major etiologic virus of human NANB hepatitis. Sciences 244: 362, 1989
Brechot C, Kremsdorf D: Genetic variation of the hepatitis C virus (HCV) genome: random events or a clinically relevant issue? J Hepatol 17: 265, 1993
Okamoto H, Sugiyama Y, Okada S et al.: Typing hepatitis C virus by polymerase chain reaction with typespecific primers: application to clinical surveys and tracing infection sources. J Gen Virol 73: 673, 1992
Simmonds P, McOmis F, Yap PL et al.: Sequence variability in the 5’ non coding region of hepatitis C virus: identification of a new virus type and restriction on sequence diversity. J Gen Virol 74: 661, 1993
Nakatsuji Y, Matsumoto A, Ogata H, Kiyosawa K: Detection of chronic hepatitis C virus infection by four diagnostic systems: first generation and second generation enzyme linked immunosorbent assay, second generation enzyme linked immunosorbent assay, second generation immunoblot assay, second generation recombinant immunoblot assay and nested polymerase chain reaction analysis. Hepatology 16: 300, 1992
Van der Poel CL, Cuypers HT, Reesink HW et al.: Confirmation of hepatitis C virus infection by new four antigen recombinant immunoblot assay. Lancet 337: 317, 1991
Zaaijer HL, Cuypers HTM, Reesink HW, Winkel IN, Gerken G, Lelie PN: Reliability of polymerase chain reaction for detection of hepatitis C virus. Lancet 341: 722, 1993
Lau JYN, Davis GL, Kniffen J et al.: Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet 341: 1501, 1993
Tremolada F, Casarin C, Alberti A et al.: Long term follow-up of non-A, non-B (type C) post transfusion hepatitis. Hepatology 16: 273, 1992
Chan TM, Lok ASF, Cheng IKP, Chan RT: Prevalence of hepatitis C virus infection in hemodialysis patients: a longitudinal study comparing the results of RNA and antibody assays. Hepatology 17: 5, 1993
Almroth G, Ekermo B, Franzen L, Hed J: Antibodies responses to hepatitis C virus and its modes of transmission in dialysis patients. Nephron 59: 232, 1991
Camarelo C, Ortiz A, Aguilera B et al.: Liver disease patterns in hemodialysis patients with antibodies to hepatitis C virus. Am J Kidney Dis 22: 822, 1993
Mondelli MU, Smedile V, Piazza V et al.: Abnormal alanine aminotransferase activity reflects exposure to hepatitis C virus in haemodialysis patients. Nephrol Dial Transplant 6: 480, 1991
Stempel CA, Lake J, Kuo G, Vincenti F: Hepatitis C — its prevalence in end-stage renal failure patients and clinical course after kidney transplantation. Transplantation 55: 273, 1993
Vandelli L, Medici G, Savazzi AM et al.: Behavior of antibody profile against hepatitis C virus in patients on maintenance hemodialysis. Nephron 61: 260, 1992
Yamaguchi K, Nishimura Y, Fukioka N et al.: Hepatitis C virus antibodies in hemodialysis patients. Lancet 335: 1409, 1990
Kallinowski B, Theilmann L, Gmelin K et al.: Prevalence of antibodies to hepatitis C virus in hemod alysis patients. Nephron 59: 236, 1991
Elisaf M, Tsianos E, Mavridis A, D2ardamanis M, Pappas M, Siamopoulos KC: Antibodies against hepatitis C virus (anti-HCV) in haemodialysis patients: association with hepatitis B serological markers. Nephron Dial Transplant 6: 476, 1991
Knudsen F, Wantzin P, Rasmussen K et al.: Hepatitis C in dialysis patients: relationship to blood transfusions, dialysis and liver disease. Kidney Int 43: 1353, 1993
Schauer PJ, Ashrafzadeh P, Sherlock S, Brown D, Dusheiko G: The pathology of hepatitis C. Hepatology 15: 567, 1992
Gilli P, Moretti M, Soffritti S, Menini C: Anti-HCV positive patients in dialysis units? Lancet 336: 243, 1990
Agnello V, Chung RT, Kaplan LM: A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med 327: 1490, 1992
Johnson RJ, Gretch DR, Yamabe H et al.: Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med 328: 1465, 1993
Tran A, Quaranta JF, Benzaken S et al.: High prevalence of thyroid autoantibodies in a prospective series of patients with chronic hepatitis before interferon therapy. Hepatology 18: 253, 1993
Haddad J, Deny P, Munz-Gotheil C et al.: Lymphocytic sialadenitis of Sjogren’s syndrome associated with chronic hepatitis C virus liver disease. Lancet 339: 321, 1992
Fargion S, Piperno A, Capellini M et al.: Hepatitis C virus and porphyria cutanea tarda; evidence for a strong association. Hepatology 16: 1322, 1992
Seef LB, Buskell Bales Z, Wright EC et al.: Long term mortality after transfusion associated non-A, non-B hepatitis. N Engl J Med 327: 1906, 1992
Gordon SC, Elloway RS, Long JC, Dmuchowski CF: The pathology of hepatitis C as function of mode of transmission: blood transfusion vs. intravenous drug use. Hepatology 18: 1338, 1993
Caporaso N, Romano M, Marmo RS et al.: Hepatitis C virus infection is an additive risk factor for the development of hepatocellular carcinoma in patients with cirrhosis. J Hepatol 12: 367, 1991
De Metri MS, Poussin K, Baccarini P et al.: HCV-associated liver cancer without cirrhosis. Lancet 345: 413, 1995
Tine F, Magrin S, Craxi A, Pagliaro L: Interferon for non-A, non-B chronic hepatitis. A meta-analysis of randomised clinical trials. J Hepatol 13: 192, 1991
Gil B, Qian C, Riezu JI, Civiera MP, Prieto J: Hepatic and extra-hepatic HCV RNA strands in chronic hepatitis C; different patterns of response to interferon treatment. Hepatology 18: 1050, 1993
Ellis ME, Alfurayh O, Halim MA et al.: Chronic nonA nonB hepatitis complicated by end-stage renal failure treated with recombinant interferon alpha. J Hepatol 18: 210, 1993
Koenig P, Vogel W, Umlauft F et al.: Interferon treatment for chronic hepatitis C infection in uremic patients. Kidney Int 45: 1507, 1994
Huang CC, Liaw YF, Lai MK, Chu SH, Chuang CK, Huang JY: The clinical outcome of hepatitis C virus antibody-positive renal allograft recipients. Transplantation 53: 763, 1992
Roth D, Zucker K, Cirocco R et al.: The impact of hepatitis C virus infection on renal allograft recipients. Kidney Int 45: 238, 1994
Pol S, Legendre C, Saltiel CW et al.: Hepatitis C virus in kidney transplant recipients. Epidemiology and impact on renal transplantation. J Hepatol 15: 202, 1992
Ponz E, Campistol JM, Bruguera M et al.: Hepatitis C virus infection among kidney transplant recipients. Kidney Int 40: 748, 1991
Rohr MS, Lesniewski RR, Rubin CA et al.: Risk of liver disease in HCV-seropositive kidney transplant recipients. Ann Surg 217: 512, 1993
Roth D, Fernandez JA, Burke GW, Esquenazi V, Miller J: Detection of antibody to hepatitis C virus in renal transplant recipients. Transplantation 51: 396, 1991
Chan TM, Lok ASF, Cheng IKP, Ng IOL: Chronic hepatitis C after renal transplantation. Transplantation 56: 1095, 1993
Fritsche C, Brandes JC, Delaney SR et al.: Hepatitis C is a poor prognostic indicator in black kidney transplant recipients. Transplantation 55: 1283, 1993
Goffin E, Pirson Y, Cornu C et al.: Outcome of HCV infection after renal transplantation. Kidney Int 45: 551, 1994
Allison MC, Mowat A, McCruden EAB et al.: The spectrum of chronic liver disease in renal transplant recipients. Quart J Med 301: 355, 1992
Aroldi A, Tarantino A, Montagnino G et al.: Renal transplant recipients and chronic liver disease: statistical evaluation of predisposing factors. Nephron 61: 290, 1992
Lau JYN, Davis GL, Brunson ME et al.: Hepatitis C virus infection in kidney transplant recipients. Hepatology 18: 1027, 1993
Chan TM, Lok ASF, Cheng IKP, Chan RT: A prospective study of hepatitis C virus infection among renal transplant recipients. Gastroenterology 104: 862, 1993
Rostaing L, Izopet J, Baron E et al.: Treatment of chronic hepatitis C with recombinant interferon alpha in kidney transplant recipients. Transplantation 59: 1426, 1995
Soulier JP, Jungers P, Zingraff J: Virus B hepatitis in hemodialysis centers. Adv Nephrol 6: 383, 1976
Reinicke V, Dybkjaer E, Poulsen H, Banke O, Lylloff K, Nordenfeit E: A study of Australia-antigen positive blood donors and their recipients with special reference to liver histology. N Engl J Med 286: 867, 1972
Couroucé-Pauty AM, Soulier JP: Further data on HBs antigen subtypes. Geographical distribution. Vox Sang 27: 533, 1974
Debure A, Degos F, Degott C et al: Liver diseases and hepatic complications in renal transplant patients. Adv Nephrol 17: 375, 1988
Polakoff S, Cossart YE, Tillett HE: Hepatitis in dialysis units in the United Kingdom. Br Med J 3: 94, 1972
Pattison CP, Maynard JE, Berquist KR, Webster HM: Serological and epidemiological studies of hepatitis B in haemodialysis units. Lancet 2: 172, 1973
Dankert J, Uitentuis J, Houwen B, Tegzess AM, van der Hem GK: Hepatitis B surface antigen in environmental samples from hemodialysis units. J Infect Dis 134: 112, 1976
Maynard JE: Nosocomial viral hepatitis. Am J Med 70: 439, 1981
Heathcote H, Cameron CH, Dane DS: Hepatitis B antigen in saliva and semen. Lancet 1:71, 1974
Jadoul M, Cornu C, Pais E: Second generation tests for hepatitis C virus in hemodialysis patients. Ann Intern Med 115: 747, 1991
Chauveau P, Couroucé AM, Lemarec C: Antibodies to hepatitis C virus by second generation test in hemodialyzed patients. Kidney Int 43(Suppl 41): S149, 1993
Dentico P, Buongiorno R, Volpe A et al.: Prevalence and incidence of hepatitis C virus in hemodialysis patients: study of risk factors. Clin Nephron 38: 49, 1992
Niu MT, Coleman PJ, Alter MJ: Multicenter study of hepatitis C virus infection in chronic hemodialysis patients and hemodialysis center staff members. Am J Kidney Dis 22: 568, 1993
Simon N, Couroucé AM, Le Marrec N, Ducamp S: A twelve year natural history of hepatitis C virus infection in hemodialyzed patients. Kidney Int. In press
Muller GY, Zabeleta ME, Arminio A et al.: Risk factors for dialysis-associated hepatitis C in Venezuela. Kidney Int 41: 1053, 1992
Dussol B, Chicheportiche C, Cantaloube C et al.: Detection of hepatitis C infection by polymerase chain reaction among hemodialysis patients. Am J Kidney Dis 22: 574, 1993
Bouchardeau F, Chauveau P, Le Marrec N, Girault A, Zins B, Couroucé AM: Detection of hepatitis C virus by polymerase chain reaction in hemodialyzed patients in relationship to anti-HCV status. Res Virol 144: 233, 1993
Conway M, Catterall AP, Brown EA et al.: Prevalence of antibodies to hepatitis C in dialysis patients and transplant recipients with possible routes of transmission. Nephron Dial Transplant 7: 1226, 1992
Donahue G, Munoz A, Ness PM et al.: The declining risk of post-transfusion hepatitis C virus infection. N Engl J Med 327: 369, 1992
Jeffers LJ, Perez GO, De Medina MD et al.: Hepatitis C infection in two urban hemodialysis units. Kidney Int 38: 320, 1990
Miyasaka M: Infection of hepatitis C virus in patients with chronic renal failure undergoing hemodialysis therapy and staff members. Nippon Jinzo Gakkai Shi 33: 989, 1991
Calabrese G, Vagelli G, Guaschino R, Gonella M: Transmission of anti-HCV within the household of haemodialysis patients. Lancet 338: 1466, 1991
Marchesi D, Arici C, Poletti E, Mingardi G, Minola E, Mecca G: Outbreak of non-A, non-B hepatitis in centre haemodialysis patients: a retrospective analysis. Nephrol Dial Transplant 3: 795, 1988
Niu MT, Alter MJ, Kristensen C, Margolis HS: Outbreak of hemodialysis-associated non-A, non-B hepatitis and correlation with antibody for hepatitis C virus. Am J Kidney Dis 19: 345, 1992
Pereira BJ, Milford EL, Kirkman RL, Levey AS: Transmission of hepatitis C virus by organ transplantation. N Engl J Med 325: 454, 1991
Public Health Laboratory Service: Infection risks of haemodialysis: some preventive aspects. Br Med J 3: 454, 1968
Public Health Laboratory Service Survey: Decrease in the incidence of hepatitis in dialysis units associated with prevention programme. Br Med J 4: 751, 1974
Public Health Laboratory Service: Hepatitis in retreat from dialysis units in United Kingdom in 1973. Br Med J 1: 1579, 1976
Favero MS: Recommended precautions for patients undergoing hemodialysis who have AIDS or non-A, non-B hepatitis. Infect Control 6: 301, 1985
131. Morbidity and mortality weekly report, Centers for Disease Control, Atlanta: Update: universal precautions for prevention of transmission of human immunodeficiency virus, hepatitis B virus, and other bloodborne pathogens in health-care settings. JAMA 260: 462, 1988
Vandelli L, Medici G, Savazzi AM, Lusvarghi E: Emergence of hepatitis C virus infection in haemodialysis units: must the patients be dialyzed in segregated sections? (abstract) J Am Soc Nephrol 10: 380A, 1990
Pol S, Romeo R, Zins B et al.: Hepatitis C virus RNA in anti-HCV positive hemodialyzed patients: significance and therapeutic implications. Kidney Int 44: 1097, 1993
Roggendorf M: Diagnosis and epidemiology of hepatitis C virus infection. Mitteilungen der Deutschen Arbeitsgemeinschaft fürKlinische Nephrologie 21: 99, 1992
Willems M, DeJong G, Moshage H et al.: Surrogate markers are not useful for identification of HCV carriers in chronic hemodialysis patients. J Med Virol 35: 303, 1991
Wang JT, Wang TH, Lin JT, Shen JC, Lee CZ, Chen DS: Improved serodiagnosis of posttransfusion hepatitis C virus infection by a second-generation immunoassay based on multiple recombinant antigens. Vox Sang 62: 21, 1992
Farci P, Alter HJ, Govindarajan S et al.: Lack of protective immunity against reinfection with hepatitis C virus. Science 258: 135, 1992
Krugman S, Giles JP, Hammond J: Viral hepatitis, type B (MS-2 strain): prevention with specific hepatitis B immune serum globulin. JAMA 218: 1665, 1971
Couroucé-Pauty AM, Delons S, Soulier JP: Attempt to prevent hepatitis by using specific anti-HBs immunoglobulin. Am J Med 270: 375, 1975
Iwarson S, Ahlmen J, Eriksson E et al.: Hepatitis B immune globulin in prevention of hepatitis B among hospital staff members. J Infect Dis 135: 473, 1977
Prince AM, Szmuness W, Mann MK et al.: Hepatitis B immune globulin: final report of a controlled multicentre trial of efficacy in prevention of dialysis-associated hepatitis. J Infect Dis 137: 131, 1978
Desmyter J, Bradburne AF, Vermylen C, Daneels R, Boelaert J: Hepatitis B immunoglobulin in prevention of HBs antigenaemia in haemodialysis patients. Lancet 2: 377, 1975
Surgenor DMacN, Chalmers TC, Conrad ME et al.: Clinical trials of hepatitis B immune globulin. N Engl J Med 293: 1060, 1975
Kleinknecht D, Couroucé AM, Delons S et al.: Prevention of hepatitis B in hemodialysis patients using hepatitis B immunoglobulin. Clin Nephrol 8: 373, 1977
Grady GF, Lee VA, Prince AM et al. Hepatitis B immune globulin for accidental exposure among medical personnel: final report of a multicentre controlled trial. J Infect Dis 138: 625, 1978
Wahl M, Hermodsson S, Iwarson S: Hepatitis B vaccination with short dose intervals: a possible alternative for post-exposure prophylaxis? Infection 16: 229, 1988
Iwarson S: Post-exposure prophylaxis for hepatitis B: active or passive? Lancet ii: 146, 1989
Mitsui T, Iwano K, Suzuki S et al.: Combined hepatitis B immune/globulin and vaccine for postexposure prophylaxis of accidental hepatitis B virus infection in hemodialysis staff members: comparison with immune globulin without vaccine in historical controls. Hepatology 10: 324, 1989
Szmuness W, Stevens CE, Oleszko WR, Goodman A: Passive-active immunisation against hepatitis B: immunogenicity studies in adult American. Lancet i: 575, 1981
Couroucé AM, Bouchardeau F, Le Marree N, Boulard G, Soulier JP: The use of hepatitis B vaccine as booster for donors immune to HBV for the production of hepatitis B immunoglobulin (HBIG). int Second WHO IABS Symposium on Viral Hepatitis, Basel, S. Karger, 1983, p 333
Krugman S, Giles JP, Hammond J: Viral hepatitis, type B (MS-2 strain): studies on active immunization. JAMA 217:41, 1971
Jungers P, Delagneau JF, Prunet P, Crosnier J: Vaccination against hepatitis B in hemodialysis centers. Adv Nephrol 11: 303, 1982
Hilleman MR, Buynak EB, Roehm RR, Tytell AA, Bertland AV, Lampson GP: Purified and inactivated human hepatitis B vaccine: progress report. Am J Med Sci 270: 401, 1975
Jacobson IM, Dienstag JI: Viral hepatitis vaccines. Ann Rev Med 36: 241, 1985
Stevens CE, Taylor PE, Rubenstein P et al.: Safety of the hepatitis B vaccine. N Engl J Med 312: 375, 1985
Adamowicz P, Chabanier G, Hyafil F et al.: Elimination of serum proteins and potential virus contaminants during hepatitis B vaccine preparation. Vaccine 2: 209, 1984
Maupas P, Goudeau A, Coursaget P, Drucker J: Immunization against hepatitis B in man. Lancet I: 1367, 1976
Adamowicz P, Gerfaux G, Platel A et al.: Large scale production of an hepatitis B vaccine. in Hepatitis B Vaccine, edited by Maupas P, Guesry P, Amsterdam, Elsevier-North Holland, 1981, p 37
Brummelhuis HGJ, Wilson-De Stüler LA, Raap AK: Preparation of hepatitis B vaccine by heat inactivation. in Hepatitis B Vaccine, edited by Maupas P, Guesry P, Amsterdam, Elsevier-North Holland, 1981, p 51
Zuckerman AJ: New hepatitis B vaccines. Br Med J 1: 492, 1985
Eddelston A: Modem vaccines: hepatitis. Lancet i: 1142, 1990
Neurath AR, Kent SBH, Strick NS, Taylor P, Stevens CE: Hepatitis B virus contains pre-S gene-encoded domains. Nature 315: 154, 1985
Coursaget P, Barrés JL, Chiron JP, Adamowicz P: Hepatitis B vaccines with and without polymerized albumin receptors. Lancet 1: 1152, 1985
Michel ML, Pontisso P, Sobczak E, Malpiece Y, Streek R, Tiollais P: Synthesis in animal cells of hepatitis B surface antigen particles carrying a receptor for polymerized human serum. Proc Natl Acad Sci 81: 7708, 1984
Milich D, Thornton G, Neurath R et al.: Enhanced immunogenicity of the pre-S region of hepatitis B surface antigen. Science 228: 1195, 1985
Itoh Y, Takai E, Ohnuma H et al.: A synthetic peptide vaccine involving the product of the PreS2 region of hepatitis B virus DNA: protective efficacy in chimpanzees. Proc Natl Acad Sci USA 89: 9174, 1986
Alberti A, Cavaletto D, Pontisso P, Chemello L, Tagariello G, Belussi F: Antibody response to pre-S2 and hepatitis virus induced liver damage. Lancet i: 1421, 1988
Szmuness W: Large-scale efficacy trials of hepatitis B vaccines in the USA: baseline date and protocols. J Med Virol 4: 327, 1979
Szmuness W, Stevens CE, Harley EJ et al.: Hepatitis B vaccine. Demonstration of efficacy in controlled clinical trial in a high-risk population in the United States. N Engl J Med 303: 833, 1980
Szmuness W, Stevens CE, Zang EA, Harley EJ, Kellner A: A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B): a final report. Hepatology 1: 377, 1981
Crosnier J, Jungers P, Couroucé AM et al.: Randomised placebo-controlled trial of hepatitis B surface antigen vaccine in French haemodialysis units. I. Medical staff. Lancet 1: 455, 1981
Laplanche A, Couroucé AM, Benhamou E, Jungers P, Crosnier J: Response to hepatitis B vaccine. Lancet 1: 222, 1982
Szmuness W, Stevens CE, Harley EJ: Hepatitis B vaccine in medical staff of hemodialysis units: efficacy and subtype cross-protection. N Engl J Med 307: 1481, 1982
Desmyter J, Colaert J, De Groote G et al.: Efficacy of heat-inactivated hepatitis B vaccine in haemodialysis patients and staff. Double-blind placebo-controlled trial. Lancet 2: 1323, 1983
Dienstag JI, Werner BG, Polk BH et al.: Hepatitis B vaccine in health care personnel: safety immunogenicity and indicators of efficacy. Ann Intern Med 101: 34, 1984
Goudeau A, Dubois F, Barin F, Dubois MC, Coursaget P: Hepatitis B vaccines: clinical trials in high-risk setting in France (September 1975–September 1982). in Second WHO/MBS Symposium on Viral Hepatitis, Basel, Karger, 1983, p 267
Jilg W, Lobeer B, Schmidt M, Wilkse B, Zoulek G, Deinhardt F: Clinical evaluation of a recombinant hepatitis B vaccine. Lancet 2: 1174, 1985
Scolnick EM, McLean AA, West DJ, McAller WJ, Miller WJ, Buynack EB: Clinical evaluation in healthy adults of a hepatitis B vaccine made by recombinant DNA. JAMA 251: 2812, 1984
Brown SE, Stanley C, Howard CR, Zuckerman AJ, Steward MW: Antibody responses to recombinant and plasma derived hepatitis B vaccines. Br Med J 1: 159, 1986
Hollinger FB, Troisi CI, Pepe PE: Anti-HBs responses to vaccination with a human hepatitis B vaccine made by recombinant DNA technology in yeast. J Infect Dis 153: 156, 1986
Tron F, Degos F, Bréchot C et al.: Randomized dose range study of a recombinant hepatitis B vaccine produced in mammalian cells and containing the S and PreS2 sequences. J Infect Dis 160: 199, 1989
Scheiermann N, Gesemann M, Maurer C, Just M, Berger R: Persistence of antibodies after immunization with a recombinant yeast-derived hepatitis B vaccine following two different schedules. Vaccine 8: S44, 1980
Centers for Disease Control: Recommendations for protection against viral hepatitis. Recommendations of the immunization practices advisory committee. Ann Intern Med 103: 391, 1985
Ukena T, Esber H, Bessette R, Parks T, Crockers B, Shaw FE: Site of injection and response to hepatitis B vaccine. N Engl J Med 313: 579, 1985
Centers for Disease Control: Suboptimal response to hepatitis B vaccine given by injection into the buttock. MMWR 34: 105, 1985
Weber DJ, Rutala WA, Samsa GP, Santimaw JE, Lemon SM: Obesity as a predictor of poor antibody response to hepatitis B plasma vaccine. JAMA 254: 3187, 1985
Zuckerman AJ: Appraisal of intradermal immunisation against hepatitis B. Lancet i: 435, 1987
Gonzalez ML, Usandizaga M, Alomar P et al.: Intradermal and intramuscular route for vaccination against hepatitis B. Vaccine 8: 402, 1990
Bryan JP, Sjogren MH, Macarthy P, Cox E, Legters LJ, Perine PL: Persistence of antibody to hepatitis B surface antigen after low-dose, intradermal hepatitis B immunization and response to a booster dose. Vaccine 10: 33, 1992
Payton CD, Scarisbrick DA, Sikotra S, Flower AJ: Vaccination against hepatitis B: comparison of intradermal and intramuscular administration of plasma derived and recombinant vaccines. Epidemiol Infect 110: 177, 1993
Thompson SC, Darlington R, Tallent D, Robins-Browne R, Forsyth JR: Effectiveness of low-dose intradermal hepatitis B vaccination. Five years’ experience of primary vaccination. MedJ Aust 158: 372, 1993
Coleman PJ, Shaw FE, Serovich J, Hadler SC, Margolis HS: Intradermal hepatitis B vaccination in a large hospital employee population. Vaccine 9: 723, 1991
Centers for Disease Control: Inadequate immune response among public safety workers receiving intradermal vaccination against hepatitis B, United States 1990–1991. J Am Med Assoc 266: 1138, 1991
Struve J, Aronsson B, Frenning B, Granath F, von Sydow M, Weiland O: Intramuscular versus intradermal administration of a recombinant hepatitis B vaccine: a comparison of response rates and analysis of factors influencing the antibody response. Scand J Infect Dis 24: 423, 1992
Jilg W, Schmidt M, Deinhardt F, Zachoval R: Hepatitis B vaccination: how long does protection last? Lancet 2: 458, 1984
Grob PJ, Dufek A, Joller-Jemelka HI: Hepatitis B immunization — when is a booster injection necessary? Schweiz Med Wschr 115: 394, 1985
Jungers P, Couroucé AM, Laplanche A, Benhamou E: Hepatitis B vaccine. N Engl J Med 316: 47, 1987
Couroucé AM, Laplanche A, Benhamou E, Jungers P: Long-term efficacy of hepatitis B vaccination in healthy adults. in Viral Hepatitis and Liver Disease, edited by Dienstag J, Alan R. Liss, Inc. 1988, p 1002
Jilg W, Schmidt M, Deinhardt F: Prolonged immunity after late booster doses of hepatitis B vaccine. J Infect Dis 157: 1267, 1988
Bryan JP, Sjogren MH, Macarthy P, Cox B, Kao TC, Perine PL: Dosing schedule for recombinant hepatitis B vaccine. J Infect Dis 163: 1384, 1991
Laplanche A, Couroucé AM, Benhamou E, Jungers P: Timing of hepatitis B revaccination in healthy adults. Lancet i: 1206, 1987
Strickler AC, Kibsey PC, Vellend H: Seroconversion rates with hepatitis B vaccine. Ann Intern Med 101: 564, 1984
Schaaf DM, Lender M, Suedeker P, Graham LA: Hepatitis B vaccine in a hospital. Ann Intern Med 101: 720, 1984
Francis DP, Hadler SC, Thompson SE et al.: The prevention of hepatitis with vaccine: report of the Centers for Disease Control multi-center efficacy trial among homosexual men. Ann Intern Med 97: 362, 1982
Craven DE, Awdeh ZL, Kunches LM et al.: Non responsiveness to hepatitis B vaccine in health care workers: results of revaccination and genetic typings. Ann Intern Med 105: 356, 1986
Alper CA, Kruskall MS, Marcus-Bagley D et al.: Genetic prediction of non response to hepatitis B vaccine. N Engl J Med 321: 708, 1989
Yasumura S, Shimizu Y, Yasuyama T et al.: Intradermal hepatitis B virus vaccination for low-or non-responder health care workers. Acta Med Okayama 45: 457, 1991
Denis F, Mounier M, Hessel L et al.: Hepatitis B vaccination in the elderly. J Infect Dis 149: 1019, 1984
Treadwell TL, Keeffe EB, Lake J et al.: Immunogenicity of two recombinant hepatitis B vaccines in older individuals. Am J Med 95: 584, 1993
Dienstag JL, Stevens CE, Bhan AK, Szmuness W: Hepatitis B vaccine administered to chronic carriers of hepatitis B surface antigen. Ann Intern Med 96: 575, 1982
Dienstag JL, Ryan DM: Occupational exposure to hepatitis B virus in hospital personnel: infection or immunization? Am J Epidemiol 15: 26, 1982
Kessler HA, Haris AA, Payne JA, Hudson E, Potkin B, Levin S: Antibodies to hepatitis B surface antigen as the sole hepatitis B marker in hospital personnel. Ann Intern Med 103: 21, 1985
Kalish SB, Fisher B, Wallemark CB, Chniel JS, Phair JP: Prevalence of antibody to hepatitis B virus in foreignborn hospital employees. Am J Med 83: 824, 1987
Werner BG, Dienstag JL, Kuter BJ, Polk BF, Snydman DR, Craven DE, Crumpacker CS, Platt R, Grady GF: Isolated antibody to hepatitis B surface antigen and response to hepatitis B vaccination. Ann Intern Med 103: 201, 1985
Goudeau A, Dubois F: Immune status of anti-HBc positive individuals. Lancet 1: 396, 1984
Draelos M, Morgan T, Schifman RB, Sampliner RE: Significance of isolated antibody to hepatitis B core antigen determined by immune response to hepatitis vaccination. JAMA 258: 1193, 1987
Taliani G, Lece R, Furian C, Nuti M, Bernaschi P, de Bac C: Hepatitis vaccination for a wider diagnostic purpose? Lancet 2: 173, 1984
Hadziyannis SJ, Hatzakis A: Response to hepatitis B vaccine of anti-HBc positive subject. in Hepatitis B Vaccine Symposium (Berne) New Findings and Perspectives, edited by Tron F, Marnes-la-Coquette, Pasteur Vaccins, 1984, p 33.
Kane MA, Hadler SC, Maynard JE: Antibody to hepatitis B surface antigen and screening before hepatitis vaccination. Ann Intern Med 103: 791, 1985
Perrillo RP: Screening of health care workers before hepatitis B vaccination: more questions than answers. Ann Intern Med 103: 793, 1985
Goldblum SE, Reed WP: Host defenses and immunologic alterations associated with chronic hemodialysis. Ann Intern Med 93: 597, 1980
Revillard JP: Immunologic alterations in chronic renal insufficiency. Adv Nephrol 8: 365, 1979
Chatenoud L, Herbelin A, Beaurain G, Descamps-Latscha B: Immune deficiency of the uremic patients. Adv Nephrol 19:259, 1990
Descamps-Latscha B: The immune system in endstage renal disease. Current Opinion in Nephrology and Hypertension 2: 883, 1993
Chatenoud L, Jungers P, Descamps-Latscha B: Immunological considerations of the uremic and dialyzed patient. Kidney Int 45: S92, 1994
Kurz P, Köhler H, Meuer S, Hütteroth T, Meyer zum Büschenfelde KH: Impaired cellular immune responses in chronic renal failure: evidence for a T cell defect. Kidney Int 29: 1209, 1986
Meuer SC, Hauer M, Kurz P, Meyer zum Büschenfelde KH, Köhler H: Selective blockade of the antigenreceptor mediated pathway of T cell activation in patients with impaired primary immune responses. J Clin Invest 80: 743, 1987
Chatenoud L, Dugas B, Beaurain G et al.: Presence of preactivated T-cells in hemodialyzed patients: their possible role in altered immunity. Proc Natl Acad Sci USA 83: 7547, 1986
Beaurain G, Naret C, Marcon L et al.: In vivo T cell activation in chronic uremic hemodialyzed and nonhemodialyzed patients. Kidney Int 36: 636, 1989
Dumann H, Meuer S, Meyer zum Büschenfelde KH et al.: Hepatitis B vaccination and interleukin-2 receptor expression in chronic renal failure. Kidney Int 38: 1164, 1990
Crosnier J, Jungers P, Couroucé AM et al.: Randomised placebo-controlled trial of hepatitis B surface antigen vaccine in French haemodialysis units. II. Haemodialysis patients. Lancet 1: 797, 1981
Stevens CE, Alter HJ, Taylor PE, Zang EA, Harley EJ, Szmuness W: Hepatitis B vaccine in patients receiving hemodialysis. Immunogenicity and efficacy. N Engl J Med 311: 496, 1984
Stevens CE, Szmuness W, Goodman AI, Wesely SA, Fotino M: Hepatitis B vaccine: immune responses in haemodialysis patients. Lancet 2: 1211, 1980
Bommer J, Ritz E, Andrassy K et al.: Effect of vaccination schedule and dialysis on hepatitis B vaccination response in uraemic patients. Proc Eur Dial Transplant Assoc Eur. Ren Assoc 20: 161, 1983
Bommer J, Grussendorf M, Jilg W et al.: Vaccination against hepatitis B in patients with renal insufficiency. Proc Eur Dial Transplant Assoc Eur Ren Assoc 21: 300, 1984
Köhler H, Arnold W, Renschin G, Dormeyer HH, Meyer zum Büschenfelde KH: Active hepatitis B vaccination of dialysis patients and medical staff. Kidney Int 25: 124, 1984
De Graff PA, Dankert J, De Zeeuw D, Gips CH, van der Hem GK: Immune response to two different hepatitis B vaccines in haemodialysis patients: a 2-year follow-up. Nephron 40: 155, 1985
Carreno V, Mora I, Escuin F et al.: Vaccination against hepatitis B in renal dialysis units: short or normal vaccination schedule? Clin Nephrol 24: 215, 1985
Lelie PN, Reesink HW, De Jong-Van Manen S, Dees PJ, Rearink-Brongers EE: Immune response to heat-inactivated hepatitis B vaccine in patients undergoing hemodialysis. Enhancement of the response by increasing the dose of hepatitis B surface antigen from 3 to 27 μg. Arch Intern Med 145: 305, 1985
Van Geelen JA, Schalm SW, De Visser EM, Heigtink RA: Immune response to hepatitis B vaccine in hemodialysis patients. Nephron 45: 216, 1987
Pasko MT, Bartholomew WR, Beam TR, Jr, Amsterdam D, Cunningham EE: Long-term evaluation of the hepatitis B vaccine (Heptavax B) in hemodialysis patients. Am J. Kidney Dis 11:316, 1988
Steketee RW, Ziamik ME, Davis JP: Seroresponse to hepatitis B vaccine in patients and staff of renal dialysis centers, Wisconsin. Am J Epidemiol 127: 772, 1988
Smit-Leijs MBL, Kramer P, Heijtink RA, Hop WCJ, Schalm SW: Hepatitis B vaccination of haemodialysis patients: randomized controlled trial comparing plasmaderived vaccine with and without pre-S2 antigen. Eur J Clin Invest 20: 540, 1990
Albertoni F, Battilomo A, Di Nardo V et al.: Evaluation of a region-wide hepatitis B vaccination program in dialysis patients: experience in an Italian region. Nephron 58: 180, 1991
Jilg W, Schmidt M, Weinel B et al.: Immunogenicity of recombinant hepatitis B vaccine in dialysis patients. J Hepatol 3: 190, 1986
Bruguera M, Rodicio JL, Alcazar JM, Oliver A, Del Rio G, Esteban-Mur R: Effects of different dose levels and vaccination schedules on immune response to a recombinant DNA hepatitis B vaccine in haemodialysis patients. Vaccine 89(Suppl): S47, 1990
Fleming SJ, Moran DM, Cooksley WGE, Faoagali JL: Poor response to a recombinant hepatitis B vaccine in dialysis patients. J Infect 22: 251, 1991
Buti M, Viladomiu L, Jardi R et al.: Long-term immunogenicity and efficacy of hepatitis B vaccine in hemodialysis patients. Am J Nephrol 12: 144, 1992
Benhamou E, Couroucé AM, Jungers P et al.: Hepatitis B vaccine: randomized trial of immunogenicity in hemodialysis patients. Clin Nephrol 21: 143, 1984
Couroucé AM, Jungers P, Benhamou E, Laplanche A, Crosnier J: Hepatitis B in dialysis patients. N Engl J Med 311: 1515, 1984
Michel P, Janin G, El Yafi S et al.: Improvement of immune response in dialysis patients to Hevac B vaccine after multiple injections of vaccine. Proc Eur Dial Transplant Assoc Eur Ren Assoc 22: 1077, 1985
Guan R, Tay HH, Choong HL, Yap I, Woo KT: Hepatitis B vaccination in chronic renal failure patients undergoing hemodialysis: the immunogenicity of an increased dose of a recombinant DNA hepatitis B vaccine. Ann Acad Med Singapore 19: 793, 1990
Dentico P, Buongiorno R, Volpe A et al.: Long-term immunogenicity and protective efficacy of recombinant DNA yeast-derived vaccine in hemodialysis patients. J Nephrol 6: 95, 1993
Bruguera M, Cremades M, Rodicio JL et al.: Immunogenicity of a yeast-derived hepatitis B vaccine in hemodialysis patients. Am J Med 87(Suppl 3A): 30S, 1989
Joseph A, Rao TKS, Friedman EA: Long-term immunogenicity of two different four dose hepatitis B vaccination schedules in maintenance hemodialysis patients. J Am Soc Nephrol 4: 357A, 1993
Seaworth B, Drucker J, Starling J, Drucker R, Stevens C, Hamilton J: Hepatitis B vaccines in patients with chronic renal failure before dialysis. J Infect Dis 157: 332, 1988
Jungers P, Chauveau P, Couroucé AM et al.: Immunogenicity of the recombinant Genhevac B Pasteur Vaccine against hepatitis B in chronic uremic patients. J Infect Dis 169: 399, 1994
Benhamou E, Couroucé AM, Laplanche A, Jungers P, Tron F, Crosnier J: Long-term results of hepatitis B vaccination in patients on dialysis. N Engl J Med 314: 1710, 1986
Kurz P, Köhler H, Hütteroth T, Weber M, Meyer zum Büschenfelde KH: Immune defect in the early stage of chronic renal failure. Proc Eur Dial Transplant Assoc Eur Ren Assoc 22: 941, 1985
Jungers P, Chauveau P, Couroucé AM, Mattlinger B, Crosnier J: Hepatitis B vaccine in non-dialysed uraemic patients: preliminary results. Proc Eur Dial Transplant Assoc Eur Ren Assoc 22: 1073, 1985
Jungers P, Chauveau P, Loubaris T, Abbassi A, Couroucé AM: Immune response to hepatitis B vaccine in chronic uremic patients. in Progress in Hepatitis B Immunization, edited by Coursaget P, Tong MJ, John Libbey Eurotext Ltd, 1990, p 187
Walz G, Kunzendorf U, Haller H et al.: Factors influencing the response to hepatitis B vaccination of hemodialysis patients. Nephron 51: 457, 1989
Drachman R, Isacsohn M, Rudensky B, Drukker A: Vaccination against hepatitis B in children and adolescent patients on dialysis. Nephrol Dial Transplant 4: 372, 1989
Pillion G, Chiesa M, Maisin A, Schlegel N, Loirat C: Immunogenicity of hepatitis B vaccine (Hevac B) in children with advanced renal failure. Pediatr Nephrol 4: 627, 1990
Pol S, Legendre C, Mattlinger B, Berthelot P, Kreis H: Genetic basis of nonresponse to hepatitis B vaccine in hemodialized patients. J Hepatol 11: 385, 1990
Caillat-Zucman S, Gimenez JJ, Albouze G: HLA genetic heterogeneity of hepatitis B vaccine response in hemodialyzed patients. Kidney Int 41: S157, 1993
Sennesael JJ, Van der Niepen P, Verbeelen DL: Treatment with recombinant erythropoietin increases antibody titers after hepatitis B vaccination in dialysis patients. Kidney Int 40: 121, 1991
Navarro JF, Teruel JL, Mateos M, Ortuno J: Hepatitis C virus infection decreases the effective antibody response to hepatitis B vaccine in hemodialysis patients. Clin Nephrol 41: 113, 1994
Quiroga JA, Castillo I, Porres JC et al.: Recombinant gamma-interferon as adjuvant to hepatitis B vaccine in hemodialysis patients. Hepatology 12: 661, 1990
Lefebure AF, Verpooten GA, Gouttenye MM, De Broe ME: Immunogenicity of a recombinant DNA hepatitis B vaccine in renal transplant patients. Vaccine 11: 397, 1993
Rawer P, Willems WR, Breidenbach T, Guttman W, Pabst W, Schutterle G: Seroconversion rate, hepatitis B vaccination, hemodialysis, and zinc supplementation. Kidney Int 22: 149, 1987
Migneco G, Tripi S, Navetta A, La Ferla A, Vaccaro F: Serum zinc concentration and antibody response to hepatitis B vaccine in hemodialysis patients. Minerva Ped 81: 19, 1990
Kouw PM, Konings CH, De Vries PM, Van der Meulen J, Oe PL: Effects of zinc supplementation on zinc status and immunity in haemodialysis patients. J Trace Elem Electrolytes Health Dis 5: 115, 1991
Donati D, Gastaldi L: Controlled trial of thymopentin in hemodialysis patients who fail to respond to hepatitis B vaccination. Nephron 50: 133, 1988
Palestini M, Messina A, Ciaraffo S, De Sanctis GM, Errera G, Corradini SG: Brief treatment with thymopentin as adjuvant in vaccination for hepatitis B: controlled study in patients on periodic hemodialysis. Riv Eur Sci Med Farmacol 12: 135, 1990
Dumann H, Meuer SC, Renschin G, Köhler H: Influence of thymopentin on antibody response, and monocyte and T cell function in hemodialysis patients who fail to respond to hepatitis vaccination. Nephron 55: 136, 1990
Meuer SC, Hauer M, Kurz P, Meyer zum Büschenfelde KH, Köhler H: Monocyte defect in hemodialysis patients supports non-responsiveness in hepatitis B vaccination and development of HBsAg carrier state. in Viral Hepatitis and Liver Disease, edited by Zuckerman AI, New York, Alan Liss Inc, 1988, p 711
Meuer SC, Dumann H, Meyer zum BüschenfeWe KH, Köhler H: Low-dose interleukin-2 induces systemic immune responses against HBsAg in immunodeficient non-responders to hepatitis B vaccination. Lancet i: 15, 1989
Blankenstijn PJ, Van Hattum J, Boland GJ et al.: Hepatitis B vaccination of non-responder dialysis patients with recombinant hepatitis B vaccine in combination with interleukin-2. J Am Soc Nephrol 4: 334A, 1993
Jungers P, Devillier P, Salomon H, Cerisier JE, Couroucé AM: Randomised placebo-controlled trial of recombinant interleukin-2 in chronic uraemic patients who are non-responders to hepatitis B vaccine. Lancet 344: 856, 1994
Rose RM, Rey-Martinez J, Croteau C et al.: Failure of recombinant interleukin-2 to augment the primary humoral response to a recombinant hepatitis B vaccine in healthy adults. J Infec Dis 165: 775, 1992
Hibberd PL, Rubin RH: Immunization strategies for the immunocompromised host: the need for immunoadjuvants. Ann Intern Med 110: 955, 1989
Ono K, Kashiwagi S: Complete seroconversion by lowdose intradermal injection of recombinant hepatitis B vaccine in hemodialysis patients Nephron 58: 47, 1991
Waite N, Thomson L, Semple J, Goldstein M: Increase of hepatitis B antibody titre by repetitive administration of intradermal HB vaccine in chronic hemodialysis patients. J Am Soc Nephrol 3: 402A, 1992
Rodrigues I, Barros F, Guerra J, Cardoso C, Clemente J, Aguilar L: Intradermal vaccination against hepatitis B in hemodialysis patients. Influence of an immunomodulator. Rev Port Nefrol Hipert 8: 301, 1994
Poux JM, Ranger-Rogez S, Lagarde C, Benevent D, Denis F, Leroux-Robert C: Recombinant hepatitis B vaccine. Advantages of intradermal route in non-responsive dialysis patients. Presse Med 24: 803, 1995
Raine AEG, Margreiter R, Brunner FP et al.: Report on management of renal failure in Europe, XII, 1991. Nephrol Dial Transplant 7(Suppl 2): 7, 1992
Lahaye D, Strauss P, Baleux C, Van Gause W: Costbenefit analysis of hepatitis-B vaccination. Lancet ii: 441, 1987
Abiteboul D, Gouaille B: Bilan de la vaccination contre l’hépatite B à l’Assistance Publique-Hôpitaux de Paris. Bulletin Epidémiologique Hebdomadaire 41: 169, 1989
Blumberg BS: Feasibility of controlling or eradicating the hepatitis B virus. Am J Med 87(Suppl 3A): 2S, 1989
Baker CH, Breunan JM: Legal aspects of hepatitis B immunization programs. N Engl J Med 331: 684, 1984
Author information
Authors and Affiliations
Editor information
Rights and permissions
Copyright information
© 1996 Kluwer Academic Publishers
About this chapter
Cite this chapter
Degos, F., Jungers, P. (1996). Viral Infections in Dialysis Patients Part B: Dialysis Associated Hepatitis. In: Jacobs, C., Kjellstrand, C.M., Koch, K.M., Winchester, J.F. (eds) Replacement of Renal Function by Dialysis. Springer, Dordrecht. https://doi.org/10.1007/978-0-585-36947-1_49
Download citation
DOI: https://doi.org/10.1007/978-0-585-36947-1_49
Publisher Name: Springer, Dordrecht
Print ISBN: 978-0-7923-3610-5
Online ISBN: 978-0-585-36947-1
eBook Packages: Springer Book Archive